Illumina Inc. (ILMN): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Illumina ( ILMN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.9%. By the end of trading, Illumina fell $1.16 (-1.5%) to $76.68 on average volume. Throughout the day, 1,065,334 shares of Illumina exchanged hands as compared to its average daily volume of 1,038,600 shares. The stock ranged in price between $75.80-$79.09 after having opened the day at $78.49 as compared to the previous trading day's close of $77.84. Other companies within the Health Care sector that declined today were: Cytokinetics ( CYTK), down 26.9%, Pacific Biosciences of California ( PACB), down 11.7%, Arqule ( ARQL), down 10.8% and China Pharma ( CPHI), down 10.6%.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $9.7 billion and is part of the drugs industry. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 49.7%, Zalicus ( ZLCS), up 17.6%, Inovio Pharmaceuticals ( INO), up 12.9% and Tianyin Pharmaceutical ( TPI), up 12.5% , were all gainers within the health care sector with Amgen ( AMGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement